SpyGlass Pharma (SGP) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.59
- Estimate
- -$0.55
- Surprise
- -7.8%
- Score today
- 5.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
SpyGlass Pharma (SGP) reported a wider loss than forecast — adjusted EPS of -$0.59 against the -$0.55 estimate (a 7.8% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SGP Sell at 5.1/10; no pre/post engine snapshot brackets this report.
0 of the last 3 quarters beat the estimate; this quarter's -7.8% surprise compares with a -38.9% four-quarter average. Next scheduled report: 2027-03-25.
What argues against it
- Concentration risk — Pipeline: BIM-IOL System
- Quality below floor (1.6 < 4.0)
- Momentum score 3.8/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $32.24
- Price target
- $40.60
- Stop
- $29.98
- Upside to target
- +25.9%
- Reward-to-risk
- 1.7:1
Risk check: trading volume is running 2.0× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
SGP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.10B
- P/E (fwd)
- -10.8
- 52-week range
- $17.06–$39.92
- Off 52-week high
- 19.2%
- RSI (14)
- 54
- Volume vs avg
- 2.00×
- Score today
- 5.1/10